Kent Imaging Resolves ITC Dispute with MolecuLight

Kent Imaging Inc., a leading innovator in advanced diagnostic imaging technology, has reached a resolution in its ongoing dispute with MolecuLight, bringing to an end the parties' U.S. International Trade Commission (ITC) case. The resolution marks a significant step forward for the company, which has always focused on developing imaging technologies that support clinicians in making informed decisions for patient care.

SnapshotGLO, a bacterial autofluorescence imaging device, remains commercially available and in active clinical use. SnapshotGLO helps clinicians identify areas of elevated bacterial burden at the point of care, supporting wound assessment and clinical decision-making. As the only company with FDA-cleared devices for both fluorescence imaging (SnapshotGLO) and tissue oxygenation measurement (SnapshotNIR), Kent Imaging continues to support healthcare professionals who rely on its products.

SnapshotGLO, a registered trademark of Kent Imaging Inc., is part of the Snapshot product suite. The suite now includes SnapshotNIR, a near-infrared tissue oxygenation imaging device initially cleared by the FDA and Health Canada in 2017 and CE-marked in 2025. SnapshotNIR is supported by clinical evidence demonstrating its role in enhancing clinical decision-making. SnapshotGLO, on the other hand, provides real-time insight into wound bioburden presence and distribution. Together, the Snapshot product family strengthens clinicians' ability to detect, direct, and protect wounds, promoting treatment consistency and supporting improved workflow, ultimately contributing to better patient care worldwide.

SnapshotNIR, a registered trademark of Kent Imaging Inc., was initially cleared by the FDA and Health Canada in 2017 and CE-marked in 2025. The Snapshot product suite now includes SnapshotNIR, a near-infrared tissue oxygenation imaging device, and SnapshotGLO, a bacterial autofluorescence imaging device. SnapshotNIR is supported by clinical evidence demonstrating its role in enhancing clinical decision-making, while SnapshotGLO provides real-time insight into wound bioburden presence and distribution. Together, the Snapshot product family strengthens clinicians' ability to detect, direct, and protect wounds, promoting treatment consistency and supporting improved workflow, ultimately contributing to better patient care worldwide.

Kent Imaging continues to advance technologies that contribute to better patient outcomes, with SnapshotGLO and SnapshotNIR at the forefront of this mission. The company's commitment to innovation and support for healthcare professionals remains unchanged, as it looks to the future with confidence and purpose.